• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by TRACON Pharmaceuticals Inc. (Amendment)

    2/14/24 4:31:59 PM ET
    $TCON
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $TCON alert in real time by email
    SC 13G/A 1 tm246286d5_sc13ga.htm SC 13G/A

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    SCHEDULE 13G/A

    Under the Securities Exchange Act of 1934
    (Amendment No. 1)*

     

    TRACON PHARMACEUTICALS, INC.
    (Name of Issuer)
     
    COMMON STOCK, $0.001 PAR VALUE PER SHARE
    (Title of Class of Securities)
     
    89237H209
    (CUSIP Number)
     
    December 31, 2023
    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

      ¨ Rule 13d-1(b)
      x Rule 13d-1(c)
      ¨ Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    (Page 1 of 14 Pages)

     

     

     

     

     

      SCHEDULE 13G

     

    CUSIP NO. 89237H209 Page 2 of 14

     

    1

    NAMES OF REPORTING PERSONS

     

    Lincoln Park Capital Fund, LLC

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3

    SEC USE ONLY

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Illinois



    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH:

    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    116,821

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    116,821

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    116,821

    10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    0.375%

    12

    TYPE OF REPORTING PERSON

     

    OO

     

     

     

     

    SCHEDULE 13G

     

    CUSIP NO. 89237H209 Page 3 of 14

     

    1

    NAMES OF REPORTING PERSONS

     

    Lincoln Park Capital, LLC

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3

    SEC USE ONLY

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Illinois



    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH:

    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    116,821

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    116,821

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    116,821

    10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    0.375%

    12

    TYPE OF REPORTING PERSON

     

    OO

      

     

     

     

    SCHEDULE 13G

     

    CUSIP NO. 89237H209 Page 4 of 14

     

    1

    NAMES OF REPORTING PERSONS

     

    Rockledge Capital Corporation

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3

    SEC USE ONLY

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Texas



    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH:

    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    116,821

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    116,821

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    116,821

    10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    0.375%

    12

    TYPE OF REPORTING PERSON

     

    CO

       

     

     

     

    SCHEDULE 13G

     

    CUSIP NO. 89237H209 Page 5 of 14

     

    1

    NAMES OF REPORTING PERSONS

     

    Joshua B. Scheinfeld

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3

    SEC USE ONLY

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States



    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH:

    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    116,821

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    116,821

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    116,821

    10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    0.375%

    12

    TYPE OF REPORTING PERSON

     

    IN

      

     

     

     

     

    SCHEDULE 13G

     

    CUSIP NO. 89237H209 Page 6 of 14

     

    1

    NAMES OF REPORTING PERSONS

     

    Alex Noah Investors, Inc.

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3

    SEC USE ONLY

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Illinois



    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH:

    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    116,821

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    116,821

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    116,821

    10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    0.375%

    12

    TYPE OF REPORTING PERSON

     

    CO

       

     

     

     

    SCHEDULE 13G

     

    CUSIP NO. 89237H209 Page 7 of 14

     

    1

    NAMES OF REPORTING PERSONS

     

    Jonathan I. Cope

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3

    SEC USE ONLY

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States



    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH:

    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    116,821

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    116,821

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    116,821

    10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    0.375%

    12

    TYPE OF REPORTING PERSON

     

    IN

      

     

     

     

     

    SCHEDULE 13G

     

    CUSIP NO. 89237H209 Page 8 of 14

     

    Item 1.  
       
      (a) Name of Issuer:
         
        TRACON Pharmaceuticals, Inc., a Delaware corporation (the “Issuer”)
         
      (b) Address of Issuer’s Principal Executive Offices:
         
        4350 La Jolla Village Drive, Suite 800
        San Diego, California 92122
         
    Item 2.  
       
      (a) Name of Person Filing:
         
        Lincoln Park Capital Fund, LLC (“LPC Fund”)
        Lincoln Park Capital, LLC (“LPC”)
        Rockledge Capital Corporation (“RCC”)
        Joshua B. Scheinfeld (“Mr. Scheinfeld”)
        Alex Noah Investors, Inc. (“Alex Noah”)
        Jonathan I. Cope (“Mr. Cope” and, collectively with LPC Fund, LPC, RCC, Mr. Scheinfeld and Alex Noah, the “Reporting Persons”)
         
      (b) Address of Principal Business Office, or if None, Residence:
         
        The address of the principal business office of each of the Reporting Persons is:
        440 North Wells, Suite 410
        Chicago, Illinois 60654
         
      (c) Citizenship:
         
        LPC Fund is an Illinois limited liability company
        LPC is an Illinois limited liability company
        RCC is a Texas corporation
        Mr. Scheinfeld is a United States citizen
        Alex Noah is an Illinois corporation
        Mr. Cope is a United States citizen

     

     

     

     

     

    SCHEDULE 13G

     

    CUSIP NO. 89237H209 Page 9 of 14

     

      (d) Title of Class of Securities:
         
        Common Stock, par value $0.001 per share (“Common Stock”)
         
      (e) CUSIP Number:
         
        89237H209

     

    Item 3.

     

    If this statement is filed pursuant to §§240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a) ¨ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o).
    (b) ¨ Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c).
    (c) ¨ Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c).
    (d) ¨ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
    (e) ¨ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
    (f) ¨ An employee benefit plan or endowment fund in accordance with §240. 13d-1(b)(1)(ii)(F);
    (g) ¨ A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
    (h) ¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j) ¨ A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
    (k) ¨ Group, in accordance with §240.13d-1(b)(1)(ii)(K).
         
    If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution ______________________

     

     

     

     

     

    SCHEDULE 13G

     

    CUSIP NO. 89237H209 Page 10 of 14

     

    Item 4. Ownership.

     

    Reporting person  Amount
    beneficially
    owned1:
      Percent
    of class2:
      Sole power
    to vote or
    direct
    the vote:
      Shared power
    to vote or
    to direct
    the vote:
      Sole power
    to dispose or to
    direct the
    disposition of:
      Shared power
    to dispose or to
    direct the
    disposition of:
    Lincoln Park Capital Fund, LLC  116,821  0.375%  0  116,821  0  116,821
    Lincoln Park Capital, LLC  116,821  0.375%  0  116,821  0  116,821
    Rockledge Capital Corporation  116,821  0.375%  0  116,821  0  116,821
    Joshua B. Scheinfeld  116,821  0.375%  0  116,821  0  116,821
    Alex Noah Investors, Inc.  116,821  0.375%  0  116,821  0  116,821
    Jonathan I. Cope  116,821  0.375%  0  116,821  0  116,821

     

    1 Represents (i) 81,423 shares of Common Stock and (ii) up to 35,398 shares of Common Stock issuable upon the exercise of Common Stock purchase warrants purchased by LPC Fund directly from the Issuer in March 2018 (the “Warrants”), which are currently exercisable at a price of $27.00 per share (subject to adjustment as provided in the Warrants), subject to a 9.99% beneficial ownership cap that prohibits the issuance of shares of Common Stock upon exercise of the Warrant to the extent such issuance would cause the holder’s beneficial ownership of Common Stock (as calculated pursuant to Section 13(d) of the Act and Rule 13d-3 promulgated thereunder) to exceed 9.99% of the outstanding Common Stock. The Warrants expire on March 27, 2024.
    2 Based on the information contained in the Issuer’s Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on November 9, 2023, there was a total of 31,144,335 shares of common stock outstanding as of November 3, 2023, which number of outstanding shares excludes the 35,398 shares of Common Stock issuable upon exercise of the Warrants, as set forth in footnote 1 above. The percentage is calculated as of November 3, 2023, and includes the 81,423 shares of Common Stock purchased by LPC Fund directly from the Issuer, and also assumes that all of the shares of Common Stock currently underlying the Warrants were issued and outstanding as of December 31, 2023.

     

     

     

     

    SCHEDULE 13G

     

    CUSIP NO. 89237H209 Page 11 of 14

     

    As of December 31, 2023, LPC Fund beneficially owned, directly, (i) 81,423 shares of Common Stock and (ii) 35,398 shares of Common Stock currently underlying the Warrants, which Warrants were outstanding and exercisable as of December 31, 2023.

     

    LPC is the Managing Member of LPC Fund. RCC and Alex Noah are the Managing Members of LPC. Mr. Scheinfeld is the president and sole shareholder of RCC, as well as a principal of LPC. Mr. Cope is the president and sole shareholder of Alex Noah, as well as a principal of LPC. As a result of the foregoing, Mr. Scheinfeld and Mr. Cope have shared voting and shared investment power over the shares of Common Stock of the Issuer held directly by LPC Fund.

     

     Pursuant to Section 13(d) of the Act and the rules thereunder, each of LPC, RCC, Mr. Scheinfeld, Alex Noah, and Mr. Cope may be deemed to be a beneficial owner of the shares of Common Stock of the Issuer beneficially owned directly by LPC Fund.

     

    The foregoing should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of any shares of Common Stock owned by another Reporting Person. Pursuant to Rule 13d-4 of the Act, each of LPC, RCC, Mr. Scheinfeld, Alex Noah, and Mr. Cope disclaims beneficial ownership of the shares of Common Stock of the Issuer held directly by LPC Fund.

     

     

     

     

     

     

    SCHEDULE 13G

     

    CUSIP NO. 89237H209 Page 12 of 14

     

    Item 5. Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following x.

     

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person.

     

    Not applicable.

     

    Item 7. Identification and Classification of Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

     

    Not applicable.

     

    Item 8. Identification and Classification of Members of the Group.

     

    Not applicable.

     

    Item 9. Notice of Dissolution of Group.

     

    Not applicable.

     

    Item 10. Certifications.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

     

    SCHEDULE 13G

     

    CUSIP NO. 89237H209 Page 13 of 14

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: February 14, 2024

     

    LINCOLN PARK CAPITAL FUND, LLC   LINCOLN PARK CAPITAL, LLC
         
    BY: LINCOLN PARK CAPITAL, LLC   BY: ROCKLEDGE CAPITAL CORPORATION
         
    BY: ROCKLEDGE CAPITAL CORPORATION    
           
         
    By: /s/ Joshua B. Scheinfeld   By: /s/ Joshua B. Scheinfeld
      Name: Joshua B. Scheinfeld     Name: Joshua B. Scheinfeld
      Title: President     Title: President
         
    LINCOLN PARK CAPITAL FUND, LLC   LINCOLN PARK CAPITAL, LLC
         
    BY: LINCOLN PARK CAPITAL, LLC   BY: ALEX NOAH INVESTORS, INC.
         
    BY: ALEX NOAH INVESTORS, INC.    
           
         
    By: /s/ Jonathan I. Cope   By: /s/ Jonathan I. Cope
      Name: Jonathan I. Cope     Name: Jonathan I. Cope
      Title: President     Title: President
         
    ROCKLEDGE CAPITAL CORPORATION   ALEX NOAH INVESTORS, INC.
         
         
    By: /s/ Joshua B. Scheinfeld   By: /s/ Jonathan I. Cope
      Name: Joshua B. Scheinfeld     Name: Jonathan I. Cope
      Title: President     Title: President
         
    JOSHUA B. SCHEINFELD   JONATHAN I. COPE
         
         
    By: /s/ Joshua B. Scheinfeld   By: /s/ Jonathan I. Cope
      Name: Joshua B. Scheinfeld     Name: Jonathan I. Cope
      Title: President     Title: President

      

     

     

     

    SCHEDULE 13G

     

    CUSIP NO. 89237H209 Page 14 of 14

     

    LIST OF EXHIBITS

     

    Exhibit No. Description
       
    99.1 Joint Filing Agreement

     

     

     

     

     

    Get the next $TCON alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TCON

    DatePrice TargetRatingAnalyst
    2/23/2022$10.00Outperform
    Baird
    More analyst ratings

    $TCON
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3 filed by new insider Lazar David E.

      3 - Tracon Pharmaceuticals, Inc. (0001394319) (Issuer)

      5/13/24 5:00:43 PM ET
      $TCON
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Brown Scott B. was granted 3,500 shares, increasing direct ownership by 16% to 25,128 units (SEC Form 4)

      4 - Tracon Pharmaceuticals, Inc. (0001394319) (Issuer)

      3/13/24 5:59:38 PM ET
      $TCON
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Theuer Charles was granted 7,000 shares, increasing direct ownership by 2% to 406,417 units (SEC Form 4)

      4 - Tracon Pharmaceuticals, Inc. (0001394319) (Issuer)

      3/13/24 5:56:13 PM ET
      $TCON
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TCON
    Financials

    Live finance-specific insights

    See more
    • TRACON Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update

      SAN DIEGO, May 14, 2024 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (NASDAQ:TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, today announced financial results for the first quarter ended March 31, 2024. The Company will host a conference call and webcast today at 4:30 PM Eastern Time / 1:30 PM Pacific Time. "With ENVASARC fully enrolled we are focused on leveraging our Product Development Platform to generate non-dilutive capital through either an additional license or by replacing a CRO and executi

      5/14/24 4:01:00 PM ET
      $TCON
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • TRACON to Report First Quarter 2024 Financial Results and Provide Corporate Update on May 14, 2024

      SAN DIEGO, May 07, 2024 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (NASDAQ:TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, announced today that it will report its first quarter 2024 financial and operating results after the close of U.S. financial markets on Tuesday, May 14, 2024. In addition, management will host a conference call to provide an update on corporate activities and discuss the financial results. Date:May 14, 2024Time:4:30 pm Eastern Time (1:30 pm Pacific Time)Conference Call:In order t

      5/7/24 4:01:00 PM ET
      $TCON
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • TRACON Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update

      SAN DIEGO, March 05, 2024 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (NASDAQ:TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, today announced financial results for the fourth quarter and year ended December 31, 2023. The Company will host a conference call and webcast today at 4:30 PM Eastern Time / 1:30 PM Pacific Time. "We are on track to complete enrollment of 80 patients treated with single agent envafolimab in the ongoing pivotal ENVASARC trial later this quarter. We expect to report updated

      3/5/24 4:02:00 PM ET
      $TCON
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TCON
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Baird initiated coverage on TRACON Pharmaceuticals with a new price target

      Baird initiated coverage of TRACON Pharmaceuticals with a rating of Outperform and set a new price target of $10.00

      2/23/22 4:50:05 AM ET
      $TCON
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Alliance Global Partners initiated coverage on TRACON Pharmaceuticals with a new price target

      Alliance Global Partners initiated coverage of TRACON Pharmaceuticals with a rating of Buy and set a new price target of $13.00

      6/4/21 8:08:23 AM ET
      $TCON
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Tracon Pharmaceuticals upgraded by BTIG Research with a new price target

      BTIG Research upgraded Tracon Pharmaceuticals from Neutral to Buy and set a new price target of $14.00

      4/16/21 8:36:58 AM ET
      $TCON
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TCON
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by TRACON Pharmaceuticals Inc.

      SC 13G/A - Tracon Pharmaceuticals, Inc. (0001394319) (Subject)

      11/14/24 8:51:58 PM ET
      $TCON
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by TRACON Pharmaceuticals Inc. (Amendment)

      SC 13G/A - Tracon Pharmaceuticals, Inc. (0001394319) (Subject)

      4/5/24 4:10:26 PM ET
      $TCON
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by TRACON Pharmaceuticals Inc. (Amendment)

      SC 13G/A - Tracon Pharmaceuticals, Inc. (0001394319) (Subject)

      3/19/24 11:20:05 AM ET
      $TCON
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TCON
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • TRACON Pharmaceuticals Announces it Will Wind Down Operations

      SAN DIEGO, July 30, 2024 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (OTCQB:TCON) today announced that the Company has terminated its employees and will wind down its operations. This decision was made at a special meeting of the board of directors.  The board of directors appointed Craig R. Jalbert, age 62, as the Company's CEO, President, Treasurer and Secretary, and sole member of the board. Mr. Jalbert has served as a principal of the Foxborough, Massachusetts accounting firm of Verdolino & Lowey, P.C. since 1987. For over 30 years he has focused his practice in distressed businesses and has served, and continues to serve, in the capacities of officer and director for numerous firms in

      7/30/24 4:44:46 PM ET
      $TCON
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • TRACON Pharmaceuticals Announces Termination of ENVASARC Trial and Will Explore Strategic Alternatives Leveraging its In-House Product Development Platform

      The objective response rate by blinded independent central review in the fully enrolled ENVASARC pivotal trial in the 82 evaluable patients is 5% (four responders) and did not meet the primary endpoint of 11% Company will focus on exploring strategic alternatives, that may include a variety of strategic transactions such as a reverse merger, acquisition, sale of all assets, or other strategic transactions leveraging its in-house Product Development Platform of CRO-independent clinical trial execution SAN DIEGO, July 01, 2024 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON) today announced the objective response rate (ORR) by blinded independent central review (BICR) in the fully

      7/1/24 9:00:00 AM ET
      $TCON
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • TRACON Announces Publication in Clinical Cancer Research of Phase 2 Clinical Data for TRC102, a DNA Damage Repair Inhibitor, in Recurrent Glioblastoma Patients

      Publication Highlights Activity of the Combination of TRC102 and Temodar (Temozolomide) in Patients who Progressed Following Initial Treatment with Surgical Resection, Temodar and External Beam Radiotherapy Consistent with the TRC102 Mechanism of Action, Extended Survival was Demonstrated in Patients with Activation of DNA Damage Response Pathways Prior to TRC102 Treatment SAN DIEGO, June 11, 2024 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent Product Development Platform (PDP) to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science c

      6/11/24 8:00:00 AM ET
      $TCON
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TCON
    Leadership Updates

    Live Leadership Updates

    See more
    • TRACON Pharmaceuticals Announces it Will Wind Down Operations

      SAN DIEGO, July 30, 2024 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (OTCQB:TCON) today announced that the Company has terminated its employees and will wind down its operations. This decision was made at a special meeting of the board of directors.  The board of directors appointed Craig R. Jalbert, age 62, as the Company's CEO, President, Treasurer and Secretary, and sole member of the board. Mr. Jalbert has served as a principal of the Foxborough, Massachusetts accounting firm of Verdolino & Lowey, P.C. since 1987. For over 30 years he has focused his practice in distressed businesses and has served, and continues to serve, in the capacities of officer and director for numerous firms in

      7/30/24 4:44:46 PM ET
      $TCON
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • TRACON Pharmaceuticals Announces Appointment of Carol Lam to its Board of Directors

      SAN DIEGO, Oct. 13, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer and utilizing a product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., announced today the appointment of Carol Lam to its Board of Directors. "We are very pleased to welcome Carol to our Board of Directors," said Dr. Charles Theuer, President and Chief Executive Officer of TRACON. "She brings a global perspective on technology development acquired through her extensive experience as deputy General Counsel

      10/13/21 8:00:00 AM ET
      $TCON
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • TRACON Pharmaceuticals Announces Appointment of Brenda Marczi, PharmD, as Senior Vice President, Regulatory Affairs, and Granting of Inducement Award

      SAN DIEGO, July 20, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., announced today the appointment of Brenda Marczi, PharmD, as Senior Vice President, Regulatory Affairs, and the granting of an inducement equity award to Dr. Marczi. "We are very pleased to welcome Brenda to the senior management team at TRACON," said Charles Theuer, M.D., Ph.D., President and CEO of TRACON. "

      7/20/21 8:05:00 AM ET
      $TCON
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TCON
    SEC Filings

    See more
    • SEC Form 15-12G filed by TRACON Pharmaceuticals Inc.

      15-12G - Tracon Pharmaceuticals, Inc. (0001394319) (Filer)

      11/7/24 4:05:49 PM ET
      $TCON
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form EFFECT filed by TRACON Pharmaceuticals Inc.

      EFFECT - Tracon Pharmaceuticals, Inc. (0001394319) (Filer)

      11/4/24 12:15:04 AM ET
      $TCON
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form EFFECT filed by TRACON Pharmaceuticals Inc.

      EFFECT - Tracon Pharmaceuticals, Inc. (0001394319) (Filer)

      11/4/24 12:15:09 AM ET
      $TCON
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care